子宫内膜癌DACH1基因启动子甲基化的检测及其临床意义研究

DACH1 gene promoter methylation detection in endometrial cancer and its clinical significance

目的检测子宫内膜癌组织中细胞命运决定因子(DACH1)基因启动子甲基化的情况,探讨其相关的临床意义。方法收集子宫内膜癌患者85例,另取功能失调性子宫出血子宫诊刮患者子宫内膜组织30例作为对照。MSP-PCR检测DACH1基因启动子甲基化的改变。结果子宫内膜癌DACH1基因启动子甲基化的阳性率为34.1%(29/85),对照组的阳性率为6.7%(2/30),两组之间差异具有统计学意义(P<0.05)。DACH1基因启动子甲基化阳性率在子宫内膜癌临床Ⅲ、Ⅳ期、有淋巴结转移和肌层浸润深度>1/2的患者分别为45.5%、48.3%和46.9%,显著高于临床Ⅰ、Ⅱ期、无淋巴结转移和肌层浸润深度≤1/2患者的22.0%、26.8%和26.4%(P<0.05)。结论子宫内膜癌组织中DACH1基因启动子甲基化可能参与了子宫内膜的发生、发展过程,有可能作为子宫内膜癌分级、预后评估的新指标。

【Objective】To study the methylation of DACH1 gene promoter in endometrial cancer and explore its clinical significance.【Methods】A total of 85 patients with endometrial cancer were enrolled in this study. Another30 cases of endometrial tissue of dysfunctional uterine curettage were used as control. The methylation of DACH1 gene promoter was detected by MSP-PCR analysis. 【Results】The positive rate of DACH1 methylationwas 34.1%（29/85） and 6.7%（2/30） in endometrial cancer and control group,respectively. There was significant difference between the two groups（P〈0.05）. The positive rate of DACH1 methylation in endometrial cancer with clinical（Ⅲ andⅣ） stage, lymph node metastasis and depth of myometrial invasion（1/2） was 45.5%, 48.3%, and 46.9%, which was higher than that of 22.0%, 26.8%, and 26.4% in endometrial cancer with clinical（Ⅰ and Ⅱ） stage, non-lymph node metastasis and depth of myometrial invasion（≤1/2）（P〈0.05）.【Conclusion】The methylation of DACH1 gene promoter was involved in the occurrence and development of endometrial cancer, which can be used as an indicator to assess the grade and prognosis of endometrial cancer.